Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeerSEER -0.95%54 Gross Margin % is 46.84% as of Jun. 2026, which is 4% below its 10-year median of 48.99. GuruFocus rates SEER with a GF Score™ of 54/100 and a GF Value™ of $2.02 (Fairly Valued). The stock has 8 warning signs investors should review. Among 735 Biotechnology companies, Seer ranks worse than 64.35% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Seer's Gross Profit for the
three
months ended in Jun. 2026 was $1.41 Mil. Seer's Revenue for the
three
months ended in Jun. 2026 was $3.00 Mil. Therefore, Seer's Gross Margin % for the quarter that ended in Jun. 2026 was 46.84%.
The historical rank and industry rank for Seer's Gross Margin % or its related term are showing as below:
SEER'
s Gross Margin % Range Over the Past 10 Years
Min: 42.8 Med: 48.99 Max: 49.87
Current: 45.92
During the past 8 years, the highestGross Margin % of Seer was 49.87%. The lowest was 42.80%. And the median was 48.99%.
SEER's Gross Margin % is ranked worse than 64.35% of 735
companies
in the Biotechnology industry
Industry Median: 60.91
vs SEER: 45.92
Seer had a gross margin of 46.84% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Seer was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Seer had a gross margin of 46.84% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Seer Gross Margin % Related Terms
Seer Gross Margin % Historical Data
* Premium members only.
The historical data trend for Seer's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SEER vs VANI, FBIO, PMN: Gross Margin % Comparison
For the Biotechnology subindustry, Seer's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seer Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seer's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Seer's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Seer (SEER) has a Gross Margin % of 46.84% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Seer and its competitors. This is near median its historical median of 48.99. Over the past decade, Seer's Gross Margin % has ranged from 42.80 to 49.87. According to the industry distribution chart, Seer ranks #473 out of 735 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Seer's Gross Margin % too high?
Seer's current Gross Margin % of 46.84% is near median its 10-year median of 48.99. Over the past 10 years, this metric has ranged from a low of 42.80 to a high of 49.87. The Biotechnology industry median Gross Margin % is 60.91. Seer's value of 46.84% is 23.1% below this industry median. Based on the distribution chart, Seer ranks #473 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Seer has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seer's Gross Margin % compare to VANI and FBIO?
According to the Biotechnology industry distribution chart, Seer ranks #473 out of 735 companies for Gross Margin %. This places Seer in the lower half of its industry. The industry median Gross Margin % is 60.91. Seer's value of 46.84% is 23.1% below this benchmark. Historically, Seer's own Gross Margin % has ranged from 42.80 to 49.87 over the past decade. While the company's 10-year median is 48.99 vs. the industry median of 60.91, Seer has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seer's current Gross Margin % of 46.84% is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Seer and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seer's current Gross Margin % is 46.84%, which is near median its own 10-year median of 48.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Fairly Valued. The stock's GF Value™ is $2.02, compared to a current price of $2.08 — trading 3% above its estimated fair value. The current Gross Margin % is 46.84%, which is near median its 10-year median of 48.99 and 23.1% below the Biotechnology industry median of 60.91. Seer's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Seer (SEER), the current Gross Margin % is 46.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be overvalued.
The current stock price of $2.08 is trading 3% above its estimated GF Value™ of $2.02.
GuruFocus considers Seer to be Fairly Valued.
Key valuation signals for SEER:
Gross Margin %: 46.84% (near median its 10-year median of 48.99)
GF Value™: $2.02 vs. price of $2.08 (3% above fair value)
Industry Position: 23.1% below the Biotechnology median (#473 of 735)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
54GF Score
Get the complete analysis for SEER
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
